CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 80 filers reported holding CTI BIOPHARMA CORP in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28,000 | -72.3% | 6,669 | -60.0% | 0.00% | – |
| Q4 2022 | $101,000 | +320.8% | 16,685 | +295.9% | 0.00% | – |
| Q3 2022 | $24,000 | +700.0% | 4,214 | +644.5% | 0.00% | – |
| Q2 2022 | $3,000 | – | 566 | +1216.3% | 0.00% | – |
| Q1 2022 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 43 | -6.5% | 0.00% | – |
| Q3 2021 | $0 | – | 46 | +7.0% | 0.00% | – |
| Q2 2021 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 43 | -80.9% | 0.00% | – |
| Q4 2020 | $1,000 | – | 225 | +3.2% | 0.00% | – |
| Q3 2020 | $0 | – | 218 | +407.0% | 0.00% | – |
| Q2 2020 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 43 | -95.8% | 0.00% | – |
| Q3 2018 | $2,000 | +100.0% | 1,024 | +894.2% | 0.00% | – |
| Q2 2018 | $1,000 | – | 103 | +157.5% | 0.00% | – |
| Q4 2017 | $0 | – | 40 | +122.2% | 0.00% | – |
| Q3 2017 | $0 | – | 18 | +100.0% | 0.00% | – |
| Q1 2017 | $0 | – | 9 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,000,000 | $3,881,000 | 2.23% |
| BVF INC/IL | 6,929,690 | $6,723,000 | 0.75% |
| CAXTON CORP | 323,026 | $313,000 | 0.29% |
| NEA Management Company, LLC | 3,750,000 | $3,638,000 | 0.19% |
| Orbimed Advisors | 5,000,000 | $4,851,000 | 0.08% |
| Fosun International Ltd | 300,428 | $288,000 | 0.02% |
| OXFORD ASSET MANAGEMENT LLP | 105,385 | $102,000 | 0.00% |
| A.R.T. Advisors, LLC | 30,055 | $29,000 | 0.00% |
| Renaissance Technologies | 1,282,352 | $1,244,000 | 0.00% |
| WASHINGTON TRUST Co | 16,000 | $15,000 | 0.00% |